Literature DB >> 14651763

Chronic obstructive pulmonary disease: developing comprehensive management.

Barry J Make1.   

Abstract

The goals of managing chronic obstructive pulmonary disease include making the correct diagnosis, avoiding further risk (especially by smoking cessation), controlling symptoms (particularly dyspnea), and treating complications. Patients with chronic obstructive pulmonary disease can obtain substantial symptom relief from medications, including bronchodilators. Prescription of bronchodilators should be guided by the patient's degree of dyspnea, and response to initial therapy. In patients with severe disease and uncontrolled dyspnea, simultaneous use of multiple classes of bronchodilators provides additional benefit. Controlled investigations have found that patient adherence to prescribed therapies is less than optimal even in the best circumstances. Adherence barriers include factors related to the treatment, to the patient, and to the health care practitioner. Understanding these barriers and addressing patient adherence may improve outcomes. Health care practitioners need to develop an optimal working relationship with each patient and focus on their roles as educators and advocates for the patient's health. A collaborative self-management approach recognizes the patient's role in making his or her own health decisions and the physician's role as an educator and facilitator of the patient's health decisions. When multiple therapies are employed, a comprehensive management plan should be developed to help the patient understand and incorporate all the necessary treatments on an ongoing basis. Disease management programs may be useful in assisting health care practitioners and patients in managing chronic obstructive pulmonary disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14651763

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  7 in total

1.  Potential risk factors for medication non-adherence in patients with chronic obstructive pulmonary disease (COPD).

Authors:  Maher R Khdour; Ahmed F Hawwa; Joseph C Kidney; Bronagh M Smyth; James C McElnay
Journal:  Eur J Clin Pharmacol       Date:  2012-04-05       Impact factor: 2.953

2.  Onset of action of formoterol versus salmeterol via dry powder inhalers in moderate chronic obstructive pulmonary disease: a randomized, placebo-controlled, double-blind, crossover study.

Authors:  Mario Cazzola; Pierluigi Paggiaro; Paolo Palange; Leif Bjermer; Pilar Ausin; Lars-Goran Carlsson; Jan Ekelund; Jan Lotvall
Journal:  Clin Drug Investig       Date:  2012-03-01       Impact factor: 2.859

3.  Bronchodilator Efficacy of a Single-Dose 12/400-µg Formoterol/Budesonide Combination as a Dry Powder for Inhalation Delivered by Discair® in Adult Patients with Moderate-to-Severe Stable COPD: Open-Label, Single-Arm, Phase IV Trial.

Authors:  Pinar Yildiz; Mesut Bayraktaroglu; Didem Gorgun; Kivanc Yuksel
Journal:  Clin Drug Investig       Date:  2019-10       Impact factor: 2.859

Review 4.  Patient adherence in COPD.

Authors:  J Bourbeau; S J Bartlett
Journal:  Thorax       Date:  2008-09       Impact factor: 9.139

5.  Roflumilast: the evidence for its clinical potential in the treatment of chronic obstructive pulmonary disease.

Authors:  Linda Timm Wagner; Charlotte A Kenreigh
Journal:  Core Evid       Date:  2005-03-31

6.  Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.

Authors:  Anthony D D'Urzo; Stephen I Rennard; Edward M Kerwin; Victor Mergel; Anne R Leselbaum; Cynthia F Caracta
Journal:  Respir Res       Date:  2014-10-14

Review 7.  Medication adherence issues in patients treated for COPD.

Authors:  Ruben D Restrepo; Melissa T Alvarez; Leonard D Wittnebel; Helen Sorenson; Richard Wettstein; David L Vines; Jennifer Sikkema-Ortiz; Donna D Gardner; Robert L Wilkins
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.